Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 10/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28453321 | 0.80 | PYCR1 (0.72) | PYCR1MAOBCYP3A4LMNAUSP2 | |
| SCHEMBL21444971 | 0.79 | LOXL2 (0.50) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1174217 | 0.78 | MAOB (0.64) | PYCR1MAOBCYP3A4LMNAUSP2 | |
| SCHEMBL13259183 | 0.74 | MAOB (0.64) | PYCR1MAOBCYP3A4LMNAUSP2 | |
| SCHEMBL22403817 | 0.73 | PYCR1 (0.35) | PYCR1MAOBCYP3A4LMNAUSP2 | |
| SCHEMBL27371712 | 0.72 | HRH3 (0.63) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6637369 | 0.71 | HRH3 (0.60) | LMNAUSP2ALDH1A1HDAC8LOXL2 | |
| SCHEMBL4787627 | 0.71 | USP2 (0.41) | PYCR1MAOBCYP3A4LMNAUSP2 | |
| SCHEMBL2574518 | 0.70 | — | — | |
| SCHEMBL7413209 | 0.70 | CYP1A2 (0.43) | CYP3A4LMNATSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241014-B2 | Antimicrobial coatings and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200281205-A1 | ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THEREOF | NATIONAL SCIENCE FOUNDATION | 2020-09-10 | — | — | US | disclosed |
| US-20180030165-A1 | Polycations and Methods of Making and Using Thereof | NATIONAL SCIENCE FOUNDATION | 2018-02-01 | — | — | US | disclosed |
| US-20180030165-A1 | Polycations and Methods of Making and Using Thereof | NATIONAL SCIENCE FOUNDATION | 2018-02-01 | — | — | US | disclosed |
| WO-2017210347-A1 | ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281205-A1 | ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THEREOF | MPO, LPO, CUTA | PYCR1 1808/4885MAOB 1193/4885CYP3A4 3484/4885 |
| US-11241014-B2 | Antimicrobial coatings and methods of making and using thereof | MPO, LPO, CUTA | PYCR1 1808/4885MAOB 1193/4885CYP3A4 3484/4885 |
| US-20180030165-A1 | Polycations and Methods of Making and Using Thereof | POLI, PARG, PCNA | PYCR1 1178/4885MAOB 3592/4885CYP3A4 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.